slot super ace jili games tips and tricks
Kurt Busch, one of NASCAR's celebrated champions, is taking time out from his racing career to embrace the more personal side of life. Since retiring from full-time racing in 2023, the accomplished driver with 34 race victories, who also claimed the 2004 Cup Series Championship and won the 2017 Daytona 500, took his girlfriend to Disneyland. Busch's return to Disneyland is his first since he was 12 years old, and he shared the experience with his followers on X with the playful caption: "Warning! Here comes my Disneyland photo dump. I haven't been here since I was 12 years old. Thanks @Disneyland, we had a blast!" His post featured pictures and video of the couple. Warning! Here comes my Disneyland photo dump I haven’t been here since I was 12yr old. Thanks @Disneyland we had a blast! pic.twitter.com/rXY69ozsPA Busch and Moore also attended an NFL game at the Bank of America Stadium, witnessing the Kansas City Chiefs face off against the Carolina Panthers, and supported his brother, Kyle Busch, at a USAC Midget Series race in Ventura, California. Fans eagerly commented on his posts, sharing their well-wishes during the NASCAR off-seasons. Comments flooded in, with one fan saying, "Looks like you two had lots of fun! Merry Christmas!" Another commented on how crazy it would be to run into the driver at Disneyland: "Imagine going to Cars Land and seeing Kurt Busch—I'd lose it!" Despite stepping away from the motorsport that defined much of his life, Busch remains connected still. His role as a motorsport consultant for 23XI Racing, a team co-owned by the legendary Michael Jordan and racer Denny Hamlin, ensures his influence within NASCAR is maintained. Earlier this year, Busch was arrested for driving under the influence of alcohol. His blood-alcohol level was 0.17% at the time of driving, with the legal limit in North Carolina being 0.08%. He later broke his silence , saying the following: "I take full responsibility for my recent DWI arrest and deeply regret my actions. I voluntarily completed a pre-trial assessment and followed all recommendations ahead of my court date. "I'm committed to making amends, ensuring this never happens again, and returning to racing with a renewed focus. Thank you to everyone who has supported me." He added: "I'm very disappointed in myself and I apologize to my family, my racing family, and to my fans. "I will work with the authorities to rectify the situation and work with the county to make it a safer place in the future." Busch faced a 60-day suspended sentence, a 12-month term of unsupervised probation, and the turning over of his driving license.
Vinod Kumar is with The Times of India’s Punjab Bureau at Chandigarh. He covers news concerning Punjab politics, Health, Education, Employment and Environment. How to make healthy Oats Palak Chilla for a kid's tiffin 10 best Fried Chicken dishes from around the world 10 ways to use turmeric in winters 10 animals not allowed as pets in India 10 types of Dosa and how they are made Animals and their favourite foods 9 nuts to eat daily for hair growth in winters How to make South Indian Podi Dosa at home From tigers to cheetahs: India’s big cats and where to find them Weekend Special: How to make Multigrain ThaalipeethDaniel Penny doesn’t testify as his defense rests in subway chokehold trial
NEW YORK, Dec. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Applied Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc . Investors have until February 18, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Applied Therapeutics securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Alexandru v. Applied Therapeutics, Inc. , et al. , No. 24-cv-09715. What is the Lawsuit About? Applied Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia. During the relevant period, the Company stated that its New Drug Applications submitted to regulators for govorestat were “supported by rapid and sustained reduction in galactitol, which resulted in a meaningful benefit on clinical outcomes across pediatric patients, alongside a favorable safety profile.” Applied Therapeutics also assured investors that its tests were “performed properly” and that the Company “felt good about the quality of the data,” stating that it “took really extensive steps” and “actually videotaped” and had “master trainers” review all of the performances of the 10-meter walk-run test—the primary endpoint of the Company’s Phase III INSPIRE study for govorestat. The Stock Declines as the Truth is Revealed On November 27, 2024, Applied Therapeutics issued a press release stating that the FDA issued a Complete Response Letter for the NDA for govorestat. The Complete Response Letter stated that the FDA completed its review of the application and determined that it was unable to approve the NDA due to “deficiencies in the clinical application.” This news caused the price of Applied Therapeutics stock to fall more than 80% over the course of multiple trading days, from a closing price of $10.21 per share on November 26, 2024 to a closing price of $1.75 per share on December 2, 2024. Then, on December 2, 2024, Applied Therapeutics revealed that it received a warning letter from the FDA relating to its govorestat study discussing “issues related to electronic data capture” and “a dosing error in the dose-escalation phase of the study resulting in slightly lower levels than targeted in a limited number of patients[.]” This news caused the price of Applied Therapeutics stock to fall more than 26% over the course of multiple trading days, from a closing price of $1.75 per share on December 2, 2024 to a closing price of $1.29 per share on December 5, 2024. Click here for more information: https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc . What Can You Do? If you invested in Applied Therapeutics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc Or contact: Ross Shikowitz ross@bfalaw.com 212-789-3619 Why Bleichmar Fonti & Auld LLP? Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit https://www.bfalaw.com . https://www.bfalaw.com/cases-investigations/applied-therapeutics-inc Attorney advertising. Past results do not guarantee future outcomes.
Amazon to invest an additional $4 billion in AI startup Anthropic